Shanghai Haohai Biological Technology Co., Ltd. provided unaudited consolidated earnings guidance for the six months ending June 30, 2021. For the six months, the Group is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB 220,000,000 to RMB 250,000,000 during the Reporting Period, representing an increase of approximately RMB 192,472,800 to RMB 222,472,800, or approximately 699.21% to 808.19%, as compared to that in 2020. The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB 210,000,000 to RMB 240,000,000, representing an increase of approximately RMB 202,170,100 to RMB 232,170,100, or approximately 2,582.03% to 2,965.17%, as compared to that in 2020 .